
Progress in Medicinal Chemistry
- 1st Edition, Volume 62 - November 17, 2023
- Imprint: Academic Press
- Editors: Jonathan Bentley, Tilly Bingham
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 3 - 1 3 7 0 3 - 7
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 1 3 7 0 4 - 4
Progress in Medicinal Chemistry, Volume 62 provides a review of eclectic developments in medicinal chemistry, with each chapter written by an international board of author… Read more

Purchase options

Institutional subscription on ScienceDirect
Request a sales quote- Provides extended, timely reviews of topics in medicinal chemistry
- Contains targets and technologies relevant to the discovery of tomorrow’s drugs
- Presents analyses of successful drug discovery programs
Everyone interested in the strategy and practice of the preclinical phases of the creation of new medicines. Those wishing to understand the drivers of drug design or expand their knowledge of therapeutic target classes
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Preface
- Chapter One Antibody drug conjugates beyond cytotoxic payloads
- Abstract
- 1 Introduction
- 2 Immunology ADC (iADC)
- 3 Oncology with other possible applications
- 4 Immunostimulatory ADC (isADC)
- 5 Unconventional ADCs
- 6 Conclusion
- References
- Chapter Two Biophysical screening and characterisation in medicinal chemistry
- Abstract
- 1 Introduction
- 2 Introduction to techniques
- 3 CASE studies
- 4 Conclusions
- References
- Chapter Three Covalent fragment libraries in drug discovery—Design, synthesis, and screening methods
- Abstract
- 1 Introduction
- 2 The principles of covalent inhibitor reactivity and library design
- 3 Synthesis of covalent libraries
- 4 Screening methods for covalent fragment libraries
- 5 Conclusion: Perspectives and the future of covalent fragment libraries in drug discovery
- References
- Edition: 1
- Volume: 62
- Published: November 17, 2023
- No. of pages (Hardback): 156
- No. of pages (eBook): 260
- Imprint: Academic Press
- Language: English
- Hardback ISBN: 9780443137037
- eBook ISBN: 9780443137044
JB
Jonathan Bentley
TB
Tilly Bingham
Tilly (Matilda) Bingham is a drug discoverer with over 20 years’ experience of working in the pharmaceutical R&D sector in ‘large pharma’ (Organon, Schering-Plough, MSD), Biotech (Redx Pharma), CRO (Concept Life Sciences) and is currently Executive in Residence at Cumulus Oncology. Tilly’s early career was spent working as a medicinal chemist in CNS therapeutic areas where her research focussed on design strategies for getting small molecule therapeutics across the blood brain barrier for targets including the GPCRs OX2R, V1R and CGRP. Then, as Head of Research and Operations at Redx Pharma she oversaw the discovery and development of oncology and fibrosis clinical candidates, including the clinical candidate porcupine inhibitors RXC004 (oncology), RXC006 (AZD5055, fibrosis), Pan RAF inhibitor (JZP815) and FDA approved BTK inhibitor Pirtobrutinib. As VP Science and Chief Scientific Officer at the UK CRO Concept Life Sciences she oversaw multiple research programmes and the development of new research capability across the group. In her current role as Executive in Residence at Cumulus Oncology Tilly is employing her significant expertise in pre-clinical drug discovery to accelerate oncology innovation to key value inflection points.